


Cell Reports

High-Protein Intake during Weight Loss Therapy Eliminates the Weight-Loss-Induced Improvement in Insulin Action in Obese Postmenopausal Women

Graphical Abstract



Authors

Gordon I. Smith, Jun Yoshino, Shannon C. Kelly, ..., Bruce W. Patterson, Samuel Klein, Bettina Mittendorfer

Correspondence

mittendb@wustl.edu

In Brief

Smith et al. found that high-protein intake during weight loss (WL) preserves lean tissue mass but eliminates the WL-induced improvement in muscle insulin action. The authors suggest that this occurs through increasing oxidative stress and modulating WL-induced changes in cell structure and organization.

Highlights

- A high-protein weight loss (HP-WL) diet preserves lean body mass
- A HP-WL diet prevents the WL-induced improvement in insulin sensitivity
- A HP-WL diet alters WL-induced transcriptional changes in muscle

Accession Numbers

GSE73525



High-Protein Intake during Weight Loss Therapy Eliminates the Weight-Loss-Induced Improvement in Insulin Action in Obese Postmenopausal Women

Gordon I. Smith,^{1,2} Jun Yoshino,^{1,2} Shannon C. Kelly,¹ Dominic N. Reeds,¹ Adewole Okunade,¹ Bruce W. Patterson,¹ Samuel Klein,¹ and Bettina Mittendorfer^{1,3,*}

¹Center for Human Nutrition and Atkins Center of Excellence in Obesity Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA

²Co-first author

³Lead Contact

*Correspondence: mittendb@wustl.edu

<http://dx.doi.org/10.1016/j.celrep.2016.09.047>

SUMMARY

High-protein (HP) intake during weight loss (WL) therapy is often recommended because it reduces the loss of lean tissue mass. However, HP intake could have adverse effects on metabolic function, because protein ingestion reduces postprandial insulin sensitivity. In this study, we compared the effects of ~10% WL with a hypocaloric diet containing 0.8 g protein/kg/day and a hypocaloric diet containing 1.2 g protein/kg/day on muscle insulin action in postmenopausal women with obesity. We found that HP intake reduced the WL-induced decline in lean tissue mass by ~45%. However, HP intake also prevented the WL-induced improvements in muscle insulin signaling and insulin-stimulated glucose uptake, as well as the WL-induced adaptations in oxidative stress and cell structural biology pathways. Our data demonstrate that the protein content of a WL diet can have profound effects on metabolic function and underscore the importance of considering dietary macronutrient composition during WL therapy for people with obesity.

INTRODUCTION

Insulin-resistant glucose metabolism is the most common metabolic complication associated with obesity and a key risk factor for developing type 2 diabetes (T2D) and coronary heart disease (Kirk and Klein, 2009). Weight loss (WL) induced by dietary energy restriction is the cornerstone of therapy for people who are obese, because it improves or even normalizes insulin sensitivity and related comorbidities (Klein, 2001). However, diet-induced weight loss also decreases lean tissue (including muscle) mass (Wycherley et al., 2012; Leidy et al., 2015), which could have adverse effects on physical function, particularly in populations who are at increased risk of sarcopenia, such as postmenopausal women (Samson et al., 2000; Phillips et al., 1993). Although increased protein intake during diet-induced

weight loss is often recommended, because it helps preserve lean tissue mass (Wycherley et al., 2012; Leidy et al., 2015), data from a series of studies suggest that high protein (HP) intake could have detrimental metabolic effects; acute intravenous amino acid infusion or protein ingestion reduces insulin sensitivity (Smith et al., 2015; Krebs et al., 2002; Robinson et al., 2014), and habitual HP intake is associated with insulin resistance and an increased risk of developing T2D (Linn et al., 1996; Sluijs et al., 2010; Tinker et al., 2011). The effect of increased protein intake per se on weight-loss-induced changes in insulin sensitivity and glucose homeostasis are not known because of the confounding effects of differences in weight loss and food selection and overall diet composition (e.g., consumption of dairy and meat products and saturated and unsaturated fatty acids) between groups in studies that compared HP diets with standard protein diets (Rietman et al., 2014; Wycherley et al., 2012; Schwingshackl and Hoffmann, 2013).

The major purpose of the present study was to conduct a randomized, controlled trial (RCT) to determine whether increasing protein intake as part of a macronutrient-balanced, hypocaloric diet attenuates both the weight loss-induced reduction in lean tissue mass and the beneficial effect of a targeted 8%–10% weight loss on insulin action. Postmenopausal women with obesity were randomized to one of three interventions: (1) a WL group who consumed a hypocaloric diet containing 0.8 g protein/kg body weight per day, (2) a WL-HP diet group who consumed a hypocaloric diet containing 1.2 g protein/kg body weight per day, and (3) a weight-maintenance (WM) control group. Subjects in the WL and WL-HP groups were studied before and after they lost 8%–10% of their initial body weight and were weight stable (<2% change in body weight) for 3–4 weeks, whereas subjects in the WM group were studied after a time-matched (~6 months) weight maintenance period. Insulin sensitivity was assessed by using the hyperinsulinemic-euglycemic clamp procedure (HECP) in conjunction with stable-isotope-labeled glucose tracer infusion and by evaluating muscle AKT phosphorylation. The rate of insulin-stimulated glucose uptake (glucose rate of disappearance [Rd] during the HECP) was the primary outcome. In addition, we evaluated the muscle global transcriptome and a series of factors that can influence insulin action, including: (1) the concentrations of amino acids and their

Table 1. Subject Characteristics at Screening, Energy and Macronutrient Intake during the Dietary Intervention and Diet-Induced Change in Urinary Urea Nitrogen Excretion Rate

	WM	WL	WL-HP
Subject Characteristics			
Age (years)	60 ± 1	58 ± 1	58 ± 1
BMI (kg/m ²)	36 ± 2	35 ± 1	36 ± 1
Body mass (kg)	98 ± 7	95 ± 2	93 ± 2
Fat-free mass (kg)	51 ± 2	49 ± 1	46 ± 1
Body fat (%)	49 ± 2	48 ± 1	50 ± 1
Intrahepatic triglyceride content (%)	10.2 ± 3.4	6.6 ± 1.2	8.3 ± 2.8
Intra-abdominal adipose tissue volume (cm ³)	1,596 ± 279	1,404 ± 138	1,341 ± 205
Plasma Concentrations			
Glucose (mg/dL) ^a	95 ± 5	96 ± 2	94 ± 3
Glucose, 2 hr post-OGTT (mg/dL)	143 ± 16	124 ± 8	134 ± 8
Triglycerides (mg/dL) ^a	148 ± 19	136 ± 25	95 ± 12
Total cholesterol (mg/dL) ^a	215 ± 20	215 ± 14	203 ± 10
HDL-cholesterol (mg/dL) ^a	56 ± 5	60 ± 6	59 ± 2
LDL-cholesterol (mg/dL) ^a	129 ± 19	128 ± 11	124 ± 9
Energy, Carbohydrate, and Fat Intake			
Energy (kcal/day)	1,743 ± 146	1,345 ± 57 ^b	1,389 ± 72 ^b
Carbohydrates (% total energy)	47 ± 1	49 ± 2	43 ± 1 ^{b,c}
Carbohydrates (% non-protein energy intake)	58 ± 2	63 ± 2	63 ± 2
Fat (% total energy)	34 ± 1	29 ± 2	26 ± 1 ^b
Fat (% non-protein energy intake)	42 ± 2	37 ± 2	37 ± 2
Protein Intake			
Contribution to total energy (%)	19 ± 1	22 ± 1	31 ± 1 ^{b,c}
Grams/day	81 ± 8	73 ± 4	105 ± 3 ^{b,c}
Grams/kilogram of body weight/day	0.79 ± 0.05	0.85 ± 0.04	1.25 ± 0.03 ^{b,c}
Grams/kilogram of ideal body weight ^d /day	1.18 ± 0.11	1.09 ± 0.06	1.64 ± 0.07 ^{b,c}
Urinary Urea Nitrogen Excretion Rate (g/day)			
Before the diet intervention	10 ± 2	11 ± 1	10 ± 1
After the diet intervention	8 ± 1	10 ± 1	15 ± 2 ^{b,c}

Data are expressed as mean ± SEM. WM, weight maintenance (n = 7); WL, weight loss (n = 10); WL-HP, weight-loss high-protein (n = 10); OGTT, oral glucose tolerance test; HDL, high-density lipoprotein; LDL, low-density lipoprotein. See also [Figure S4](#).

^aValues were obtained after an overnight fast.

^bValue significantly different from corresponding value in the WM group (p < 0.05).

^cValue significantly different from corresponding value in the WL group (p < 0.05).

^dIdeal body weight is the weight corresponding to a BMI of 24.9 kg/m² ([Institute of Medicine, 2005](#)).

metabolites (C3[proprionyl]- and C5[isovaleryl]- acylcarnitine) in plasma and the phosphorylation of intramyocellular amino acid targets (mammalian target of rapamycin [mTOR] and its downstream effector, 4E-BP1, and upstream regulator, AMPK) ([Newgard et al., 2009](#); [Schooneman et al., 2013](#); [Krebs et al., 2007](#); [Tsai et al., 2015](#); [Tremblay et al., 2005](#); [Saha et al., 2011](#)); (2) plasma free fatty acid (FFA) concentration ([Boden and Chen, 1995](#); [Rodén et al., 1996](#)), palmitate rate of appearance (Ra) in plasma as an index of adipose tissue lipolytic activity ([Mittendorfer et al., 2003a](#)), and the expression of selected genes involved in lipogenesis, and fatty acid oxidation and mitochondrial function in muscle; (3) the gene expression of key enzymes involved in oxidative stress defense in muscle; (4) plasma fibroblast growth factor 21 (FGF21) ([Camporez et al., 2013](#); [Mashili](#)

[et al., 2011](#); [Xu et al., 2009](#); [Markan et al., 2014](#); [Laeger et al., 2014](#)); and (5) the plasma concentration and muscle gene expression of selected inflammatory markers ([Pedersen, 2007](#); [Kirk and Klein, 2009](#)).

RESULTS

Baseline Subject Characteristics, Dietary Compliance, and Duration of the Intervention

Baseline characteristics of the study subjects in the WM, WL, and WL-HP groups were not different from each other ([Table 1](#)). During the intervention, which lasted 27.8 ± 2.8, 26.4 ± 2.9, and 27.4 ± 1.2 weeks in the WL, WL-HP, and WM groups, respectively, protein intake (assessed by food records) closely matched




Figure 1. Changes in Body Weight and Composition and Insulin-Stimulated Glucose Uptake

(A–F) Percent changes in body mass (A), intra-hepatic triglyceride (IHTG) content (B), intra-abdominal adipose tissue (IAAT) volume (C), percent contribution of fat-free mass (FFM) to total weight loss (D), and percent changes in absolute (FFM, micromoles per kilogram per minute) and relative (percent) changes in insulin-stimulated glucose rate of disappearance (Rd) (E and F) before and after the diet intervention in the weight-maintenance (WM) group (n = 7) and in subjects who consumed either the standard weight-loss diet (WL; n = 10) or the weight-loss high-protein diet (WL-HP; n = 10). Data are expressed as mean ± SEM. *Value significantly different from corresponding value in the WM group (p < 0.05). †Value significantly different from corresponding value in the WL group (p < 0.05). ‡Value significantly different from value in the WM and WL-HP groups (p < 0.05).

Plasma Hormone and Metabolite Concentrations

Basal insulin concentration was the same before and after the intervention in the WM group and decreased to the same extent (~30%) after weight loss in the WL and WL-HP groups (p < 0.05 versus the WM group; no difference between the WL and WL-HP groups) (Table 2). Glucose and insulin concentrations achieved during the HECF after the intervention were not different from those achieved before the intervention in all three groups (Table 2). Basal FFA concentration did not change in the WM group and decreased to the

same extent (~15%) after weight loss in the WL and WL-HP groups. During the HECF, FFA concentration decreased by ~90%, both before and after the interventions, in all three groups (Table 2). Basal branched-chain amino acid concentration was ~8% lower (p < 0.05) after weight loss in both the WL and WL-HP groups (no difference between groups), whereas basal total essential (including branched-chain) and non-essential amino acid concentrations were not affected by weight loss in either the WL group or the WL-HP group. During the HECF, the sum of all (total) and non-essential amino acid concentrations decreased to the same extent in all three groups before and after the intervention. In contrast, the HECF-induced decreases in branched-chain and total essential (including branched-chain) amino acid concentrations were ~15% greater (p < 0.05) after than before weight loss in both the WL and WL-HP groups (Table 2; Figure S1). Plasma C3 and C5 acylcarnitine concentrations did not change in the WM group and tended to decrease by ~15% (p = 0.11) after weight loss in both the WL and WL-HP groups (no difference between groups) (Table 2). FGF21 concentrations were not different between groups at baseline and decreased by ~25% in both the WL and WL-HP groups (p < 0.05 versus the WM group; no difference between the WL and WL-HP groups) but did not change in the WM group (Table 2).

Changes in Body Weight and Composition

Body weight and body composition in the WM group did not change during the intervention. Both the WL and WL-HP groups lost ~10% of their initial body weight, but the contribution of fat-free mass (FFM) to total weight loss was ~45% less in the WL-HP group than in the WL group (p = 0.03) (Figure 1). However, the absolute loss of FFM was small, so that only ~700 g of FFM were preserved in the WL-HP compared with the WL group. Intrahepatic triglyceride (IHTG) content and intra-abdominal adipose tissue (IAAT) volume did not change in the WM group but decreased by ~45% (IHTG) and ~20% (IAAT), respectively, in both the WL and WL-HP groups (p < 0.01 versus the WM group; there was no difference between the WL and WL-HP groups) (Figure 1).

Table 2. Plasma Hormone and Metabolite Concentrations and Glucose Kinetics Before and After the Dietary Intervention

	WM		WL		WL-HP	
	Before	After	Before	After	Before	After
Plasma Hormone and Metabolite Concentrations						
Glucose (mg/dL)						
Basal	96.2 ± 4.1	94.7 ± 4.3	96.1 ± 3.1	92.9 ± 1.8	92.2 ± 1.3	91.9 ± 1.9
HECP	102.3 ± 1.3 ^a	102.4 ± 0.9 ^a	101.2 ± 1.0 ^a	102.5 ± 1.0 ^a	100.5 ± 0.9 ^a	101.6 ± 1.4 ^a
Insulin (μU/mL)						
Basal	8.2 ± 1.5	7.0 ± 1.5	5.9 ± 1.1	3.5 ± 0.5 ^b	7.7 ± 1.3	5.0 ± 0.8 ^b
HECP	56.6 ± 6.7 ^a	57.0 ± 2.2 ^a	53.3 ± 5.3 ^a	55.2 ± 5.2 ^a	66.3 ± 5.1 ^a	63.1 ± 5.4 ^a
Free Fatty Acids (mM)						
Basal	0.71 ± 0.06	0.70 ± 0.04	0.64 ± 0.04	0.54 ± 0.04 [†]	0.71 ± 0.06	0.61 ± 0.02 ^b
HECP	0.10 ± 0.02 ^a	0.07 ± 0.01 ^a	0.06 ± 0.01 ^a	0.04 ± 0.01 ^a	0.05 ± 0.01 ^a	0.03 ± 0.01 ^a
Branched-Chain Amino Acids (μM)						
Basal	377 ± 19	385 ± 18	375 ± 8	339 ± 15 ^b	386 ± 13	361 ± 8 ^b
HECP	237 ± 29 ^a	235 ± 25 ^a	209 ± 14 ^a	159 ± 12 ^{a,b}	216 ± 13 ^a	183 ± 12 ^{a,b}
Essential Amino Acids (μM)						
Basal	907 ± 75	942 ± 75	845 ± 25	818 ± 44	830 ± 31	856 ± 41
HECP	661 ± 87 ^a	664 ± 77 ^a	558 ± 45 ^a	468 ± 52 ^{a,b}	580 ± 41 ^a	533 ± 32 ^{a,b}
Non-essential Amino Acids (μM)						
Basal	1,006 ± 90	998 ± 98	921 ± 48	881 ± 53	954 ± 36	882 ± 53
HECP	846 ± 91 ^a	799 ± 85 ^a	709 ± 49 ^a	616 ± 55 ^a	770 ± 43 ^a	684 ± 39 ^a
Total Amino Acids (μM)						
Basal	1,913 ± 164	1,940 ± 172	1,766 ± 69	1,699 ± 92	1,784 ± 61	1,738 ± 87
HECP	1,507 ± 174 ^a	1,463 ± 158 ^a	1,268 ± 86 ^a	1,083 ± 104 ^a	1,349 ± 80 ^a	1,217 ± 64 ^a
Sum of C3 and C5 acylcarnitines (μM)	0.37 ± 0.05	0.37 ± 0.05	0.39 ± 0.03	0.32 ± 0.02	0.36 ± 0.03	0.32 ± 0.02
Fibroblast growth factor 21 (pg/mL)	219 ± 46	247 ± 52	177 ± 36	148 ± 24 ^b	168 ± 25	116 ± 13 ^b
Glucose Kinetics						
Basal Glucose Ra						
μmol/min	761 ± 15	780 ± 30	789 ± 36	736 ± 25 ^b	784 ± 31	713 ± 26 ^b
μmol/kg FFM/min	15.7 ± 0.6	16.0 ± 0.6	16.3 ± 0.7	15.8 ± 0.6	17.2 ± 0.7	16.0 ± 0.6
GIR during the HECP						
μmol/min	2,619 ± 554	2,601 ± 429	2,512 ± 197	2,986 ± 164 ^{b,c}	2,893 ± 337	2,798 ± 289
μmol/kg FFM/min	55.7 ± 13.2	55.0 ± 10.6	52.6 ± 4.9	64.6 ± 4.5 ^{b,c}	63.2 ± 6.9	62.8 ± 6.3
Glucose Rd during the HECP						
μmol/min	2,741 ± 537	2,681 ± 383	2,649 ± 214	3,108 ± 184 ^{b,c}	2,976 ± 317	2,905 ± 270
μmol/kg FFM/min	58.2 ± 12.9	56.5 ± 9.6	55.5 ± 5.3	67.3 ± 5.0 ^{b,c}	65.0 ± 6.5	65.2 ± 5.9

Data are expressed as mean ± SEM. WM, weight maintenance (n = 7); WL, weight loss (n = 10); WL-HP, weight-loss high-protein (n = 10); HECP: hyperinsulinemic-euglycemic clamp procedure; Ra, rate of appearance; FFM, fat-free mass; GIR, glucose infusion rate; Rd, rate of disappearance. See also Figure S1.

^aValue significantly different from corresponding basal value (p < 0.05).

^bValue significantly different from corresponding value in the WM group (p < 0.05).

^cValue significantly different from corresponding value in the WL-HP group (p < 0.01).

Glucose Kinetics

Basal glucose Ra and glucose Rd during the HECP in the WM group did not change during the intervention (Table 2). Basal glucose Ra decreased by ~6% after weight loss in both the WL and WL-HP groups (p < 0.05 versus the WM group; no difference between the WL and WL-HP groups) (Table 2). Glucose Ra during the HECP was almost completely (by 85% ± 2%) suppressed in all studies, both before and after weight loss (main effect of clamp, p < 0.001; no significant interactions and no sig-

nificant main effects of either group or time) (Table 2). Glucose Rd during the HECP increased by 25.3% ± 6.5% (p < 0.01) after weight loss in the WL group, whereas glucose Rd during the HECP after weight loss was not different from before weight loss in the WL-HP group (Figure 1).

By chance, baseline mean glucose Rd during the clamp procedure was 12% higher in the WL-HP group than in the WL and WM groups. This difference was largely driven by one person whose baseline glucose Rd was 5,528 μmol/min (nearly double




Figure 2. Intramyocellular Signaling Elements Before and After Weight Loss

Weight-loss-induced changes in p-AKT^{Ser473} (A), p-AMPK^{Thr172} (B), p-mTOR^{Ser2448} (C), and p-4E-BP1^{Thr37/46} (D) in muscle during basal, post-absorptive conditions (white bars) and the hyperinsulinemic-euglycemic clamp (black bars) in subjects consuming the standard weight loss (WL) and weight-loss high-protein (WL-HP) diets. Data (n = 6–8) are expressed as mean ± SEM. *Value significantly different from corresponding basal value (p < 0.05). †Value significantly different from all other values (p < 0.05). #Significant main effect of clamp (p < 0.05). See also Figure S2.

nance in the WL, WL-HP, and WM groups were not different from the increases observed before the intervention (Figure 2 and S2). Muscle p-AMPK^{Thr172} was not affected by the HCEP or by weight loss/maintenance in the WL, WL-HP, and WM groups (Figure 2 and S2).

Palmitate Kinetics and the Expression of Selected Genes Involved in Lipogenesis, and Fatty Acid Oxidation and Mitochondrial Function in Muscle

Basal palmitate Ra was not different among the WM, WL, and WL-HP groups at baseline (131 ± 15, 119 ± 8, and 123 ± 9 μmol/min, respectively) and was ~15% lower (p < 0.01) after than before the interventions in all groups (118 ± 12, 100 ± 8, and 108 ± 12 μmol/min, respectively). The expression of most of the analyzed genes involved in lipogenesis (*CHREBP*, *ELOVL6*, *FADS1*, *FASN*, and *SREBF1* but not *SCD*) and fatty acid oxidation and mitochondrial

the mean value). The average value in the remaining nine subjects was 2,693 ± 158 μmol/min and nearly identical to the average glucose Rd values in the other two groups (2,741 ± 537 and 2,649 ± 214 μmol/min in the WM and WL groups, respectively). Excluding this subject from the statistical analysis does not affect the results (i.e., HP intake eliminates the weight-loss-induced improvement in insulin-mediated glucose Rd, regardless of whether this person is or is not included in the analysis).

Intramyocellular Signaling Elements

During the HCEP, muscle phosphorylated (p)-AKT^{Ser473}, p-mTOR^{Ser2448}, and p-4E-BP1^{Thr37/46} contents increased by ~50%–150% above basal values in the WM, WL, and WL-HP groups (Figures 2 and S2). The increase in p-AKT^{Ser473} during the HCEP was greater after than before weight loss (p < 0.05) in the WL group, but it did not change in the WL-HP and WM groups (Figure 2 and S2). The increases in p-mTOR^{Ser2448} and p-4E-BP1^{Thr37/46} during the HCEP after weight loss/maintenance

function (*COX4/1*, *CPT1B*, *PDK4*, *PPARGC1A*, and *UCP2* but not *ACADM*) in muscle did not change with weight loss in either the WL group or the WL-HP group (Figure 3). Muscle gene expression of *SCD* (stearoyl-coenzyme A [CoA] desaturase) and *ACADM* [acyl-CoA dehydrogenase] was lower after than before weight loss in both the WL and WL-HP groups (Figure 3).

Inflammatory and Oxidative Stress Defense Markers in Plasma and Muscle

C-reactive protein and interleukin-6 (IL6) concentrations in plasma (Figure S3) and muscle *CD68*, *IL6*, *MCP1*, and tumor necrosis factor (*TNF*) gene expression did not change during the interventions (Figure 4). Muscle *GSTA4* gene expression decreased in the WL group, and *PRDX3* gene expression increased in the WL-HP group; *SOD1* gene expression decreased after weight loss in both the WL and WL-HP groups, and *CAT* gene expression did not change in either the WL group or the WL-HP group (Figure 4).




Figure 3. Expression of Genes Involved in Lipogenesis, and Fatty Acid Oxidation and Mitochondrial Function in Muscle

(A–L) Expression of genes involved in lipogenesis (A: carbohydrate response element binding protein [*CHREBP*]; B: elongation of very long-chain fatty acid protein 6 [*ELOVL6*]; C: fatty acid desaturase 1 [*FADS1*]; D: fatty acid synthase [*FASN*]; E: stearyl Co-A desaturase (*SCD*); and F: sterol regulatory element binding transcription factor 1 [*SREBF1*]) and in fatty acid oxidation and mitochondrial function (G: acyl-coenzyme A dehydrogenase [*ACADM*]; H: cytochrome C oxidase subunit IV [*COX4I1*]; I: carnitine palmitoyl transferase 1 [*CPT1B*]; J: pyruvate dehydrogenase kinase 4 [*PDK4*]; K: peroxisome proliferator-activated receptor gamma coactivator 1 alpha [*PPARGC1A*], and L: uncoupling protein 2 [*UCP2*]) in muscle before (white bars) and after (black bars) weight loss in subjects consuming the standard weight-loss (WL) diet and weight-loss high-protein (WL-HP) diet. Data (n = 6–9) are expressed relative to the housekeeping gene and presented as mean \pm SEM, except for *ACADM*, *FASN1*, and *SCD*, which are expressed as median (quartiles). #Significant main effect of weight loss (p < 0.05). ‡Significant main effect of group (p < 0.05).

See also Table S3.

Global Muscle Gene Expression Profiling by Using the Microarray Technique

Twenty-six gene sets were similarly affected by weight loss in the WL and WL-HP groups, and 34 were differently affected by WL in the WL and WL-HP groups (Tables 3, S1, and S2). Of those, several that were related to cell structure and organization were upregulated in the WL group and not affected, or even downregulated, by weight loss in the WL-HP group. A pathway related to the regulation of signal transduction was upregulated, and an oxidative stress gene set pathway was downregulated in the WL group but not in the WL-HP group.

DISCUSSION

Although many studies have evaluated the effect of HP diets on metabolic function, the results from several systematic reviews and meta-analyses indicate that it is not possible to determine the effect of HP intake, per se, on insulin sensitivity because of differences in overall diet composition (food selection and

nutrient composition) and amount of weight loss between the HP-intervention and control groups (Rietman et al., 2014; Wycherley et al., 2012; Schwingshackl and Hoffmann, 2013). Therefore, we conducted an RCT to evaluate the effect of dietary protein intake on body composition and insulin sensitivity by providing a protein supplement to subjects during weight loss to minimize the potential confounding influences of differences in overall diet composition on our outcome measures. In addition, participants who were given a standard-protein hypocaloric diet (0.8 g protein/kg per day) and those given a HP hypocaloric diet (1.2 g protein/kg per day) were assessed before and after matched (~10%) weight loss. We found that the WL-HP diet blunted the weight loss-induced decline in FFM by ~45%. However, the clinical importance of this effect is unclear, because it represents a very small difference in loss of FFM between groups (~700 g or 1.5% of total FFM). The beneficial effect of 10% weight loss on muscle insulin action (assessed as glucose disposal rate and phosphorylation of AKT in muscle during an HECF) was eliminated by HP intake. The failure to improve




Figure 4. Expression of Genes Involved in Inflammatory and Oxidative Stress Defense Pathways in Muscle

(A–H) Expression of genes involved in inflammatory (A: cluster of differentiation 68 [*CD68*]; C: interleukin-6 [*IL6*]; E: monocyte chemoattractant protein 1 [*MCP1*]; and G: tumor necrosis factor [*TNF*]) and oxidative stress defense (B: catalase [*CAT*]; D: glutathione S-transferase alpha 4 [*GSTA4*]; F: peroxiredoxin 3 [*PRDX3*]; and H: superoxide dismutase 1 [*SOD1*]) pathways before (white bars) and after (black bars) weight loss in subjects consuming the standard weight-loss diet (WL) and weight-loss high-protein (WL-HP) diet. Data (n = 6–9) are expressed relative to the housekeeping gene and presented as mean ± SEM, except for *IL6*, *MCP1*, and *TNF*, which are expressed as median (quartiles). *Value significantly different from corresponding basal value (p < 0.05). †Value significantly different from all other values (p < 0.05). #Significant main effect of weight loss (p < 0.05). See also Figure S3 and Table S3.

loss diet can have profound effects on metabolic function and underscore the importance of considering dietary macronutrient composition in conjunction with energy content itself in weight loss therapy for people with obesity.

The mechanism(s) responsible for the adverse effect of HP intake on insulin action are unclear. Failure to improve insulin-stimulated glucose uptake in the WL-HP group compared to the WL group occurred in the absence of any major differences in body weight, body composition, plasma FFA availability, and inflammatory markers in plasma or muscle in the two groups. Data from studies conducted in cultured myotubes, isolated rat skeletal muscles, and transgenic mice have demonstrated that amino acids—particularly the branched-chain amino acid leucine—can impair insulin-mediated glucose uptake by AMPK-mediated mTOR phosphorylation and subsequent negative feedback inhibition of phosphatidylinositol 3-kinase (PI3K)-AKT signaling (Iwanaka et al., 2010; Saha et al., 2011) or possibly downstream signaling to 4E-BP1 (Tsai et al., 2015). In contrast, we recently found that these pathways were not

involved in the inhibition of insulin-mediated glucose uptake that occurred with acute protein ingestion in people (Smith et al., 2015). In the present study, we also found that chronic HP intake impaired the weight loss-induced improvement in insulin-mediated glucose uptake in the absence of differences in p-AMPK^{Thr172}, p-mTOR^{Ser2448}, and p-4E-BP1^{Thr37/46} in muscle. Data from several recent studies have implicated other amino

muscle insulin sensitivity in the WL-HP group is clinically important because it reflects a failure to improve a major pathophysiological mechanism involved in the development of T2D (Groop, 1999; Petersen and Shulman, 2002) and indicates that more insulin is required in the WL-HP group than in the WL group to dispose of a given amount of glucose. In summary, our data, therefore, demonstrate that the protein content of a weight

Although we found that HP intake during weight loss attenuates the beneficial effect of moderate weight loss on muscle insulin action, this does not mean that an HP weight loss diet necessarily results in a diminished improvement in plasma glucose homeostasis. 24-hr glycemic control is determined by both postabsorptive and postprandial plasma glucose concentrations, which are determined by glucose Ra into plasma (from endogenous and exogenous/dietary sources) and glucose Rd from plasma. Both endogenous glucose Ra and glucose Rd are regulated by insulin, and the metabolic response to insulin across the range of physiological concentrations (basal, postabsorptive to peak postprandial) differs among organs. Endogenous (mostly hepatic) glucose production is much more sensitive to insulin than is muscle glucose uptake and is nearly completely suppressed at plasma insulin concentrations that only minimally stimulate muscle glucose uptake (Conte et al., 2012). The decline in basal plasma insulin concentration after weight loss without a change in plasma glucose concentration and a slight reduction in basal glucose Ra, suggests that weight loss in both the WL and WL-HP groups may have improved hepatic insulin sensitivity. On the other hand, our use of the HECF, in conjunction with stable isotopically labeled glucose tracer infusion and an insulin infusion rate that results in systemic plasma insulin concentrations within the postprandial range, allowed us to measure muscle insulin sensitivity, and our data demonstrate that HP intake prevented the WL-induced improvement in muscle insulin sensitivity. Dietary protein is a potent insulin secretagogue (Floyd et al., 1966; Ang et al., 2012; Manders et al., 2014), which may overcome the adverse effect of protein on insulin sensitivity by increasing the secretion of insulin. In addition, protein causes greater satiation and has a greater thermogenic effect of feeding than carbohydrate and fat, which can lead to greater weight loss with an HP than a standard protein diet (Wycherley et al., 2012; Leidy et al., 2015). Therefore, the adverse effect of dietary protein on muscle insulin action could be offset by its effect on hepatic insulin sensitivity, insulin secretion, and energy balance.

In summary, the results from our study demonstrate that HP intake during weight loss helps preserve FFM but eliminates the beneficial effect of weight loss on skeletal muscle insulin action. The mechanisms responsible for the adverse effect of HP intake on muscle insulin action are not clear. Our data suggest that HP intake causes alterations in muscle cell structure and organization and oxidative stress, which are involved in preventing the therapeutic effect of weight loss on muscle insulin action, whereas changes in circulating amino acids, including branched-chain amino acids and their metabolites, plasma FGF21 concentration, muscle mTOR signaling, and inflammatory pathways in muscle, are not involved.

EXPERIMENTAL PROCEDURES

Subjects and Study Design

Thirty-four sedentary (< 1.5 hr exercise per week) and weight-stable (< 2 kg change for at least 6 months), 50- to 65-year-old postmenopausal women with obesity were included in this study (ClinicalTrials.gov number NCT01538836), which was approved by the Human Research Protection Office at the Washington University School of Medicine. Written informed consent was obtained from all subjects before their participation in the study. We specifically chose to study only postmenopausal women with obesity

because we wanted to study a population for whom weight loss with increased protein intake is often recommended to reduce the risk of sarcopenia (Houston et al., 2009; Wolfe et al., 2008).

The flow of study subjects is shown in Figure S4. All subjects were evaluated by a history and physical examination, a resting 12-lead electrocardiogram, standard blood tests, and an oral glucose tolerance test. None of the subjects had evidence of chronic illness or significant organ dysfunction (e.g., diabetes mellitus, liver cirrhosis) or were taking medications (including hormone replacement therapy) that could affect insulin or glucose metabolism, and none consumed tobacco products, reported regular consumption of >115 g of alcohol per week, or scored >2 points (out of a possible 22) on the Michigan Alcohol Screening Test.

After subjects completed body composition analyses and an HECF, they were randomized to one of three intervention groups: (1) a WM group; (2) a WL group, who consumed an energy-reduced diet containing 0.8 g protein/kg body weight per day; and (3) a WL-HP group, who consumed an energy-reduced diet containing 1.2 g protein/kg body weight per day. All outcomes were evaluated before and after subjects randomized to the weight loss groups lost 8%–10% of their body weight or a time-matched weight maintenance period for those randomized to the WM group. Twenty-seven subjects completed the study and were included in the analysis; their characteristics are shown in Table 1. The baseline characteristics of the seven subjects who dropped out of the study (Figure S4) were not different from those who completed the study (data not shown).

Outcomes Assessment

Body Composition

Fat mass and FFM were determined by using dual-energy X-ray absorptiometry (DXA; Lunar iDXA, GE Healthcare Lunar), and IAAT volume and IHTG content were determined by using MRI/spectroscopy (1.5-T superconducting magnet; Siemens), as previously described (Frimel et al., 2007; Magkos et al., 2007).

Insulin Action—HECF

Subjects were instructed to refrain from vigorous physical activities for 3 days before being admitted to the Clinical Research Unit, where they consumed a standard 800 kcal dinner (50% carbohydrate [or CHO], 30% fat, 20% protein) between 1800 hr and 1900 hr. In addition, all subjects consumed a 100-kcal liquid meal supplement (Ensure, Abbott Laboratories, containing 15% of energy as protein, 55% as carbohydrate, and 30% as fat) at baseline (before the dietary intervention); after the intervention, subjects in the WM and WL groups consumed the same liquid meal supplement, and subjects in the WL-HP group consumed a 100-kcal whey protein solution (Unjury, ProSynthesis Laboratories) containing 21 g protein. Subjects then fasted, except for water, until the next morning. At 0600 hr, catheters were inserted into an arm vein for the infusion of stable-isotope-labeled tracers, and later insulin and dextrose, and into a radial artery for blood sampling. At ~0645 hr, a constant infusion of [U - ^{13}C] $_{16}$ palmitate (infusion rate: 6 nmol \times kg body weight $^{-1}$ \times min $^{-1}$) and a primed, constant infusion of [6,6- 2H] $_2$ glucose (priming dose: 22 μ mol \times kg body weight $^{-1}$; infusion rate: 0.22 μ mol \times kg body weight $^{-1}$ \times min $^{-1}$), both purchased from Cambridge Isotope Laboratories, were started and maintained for 4 hr. Upon completion of the basal period, an HECF was initiated with two 5-min priming doses (first 200 mU \times m $^{-2}$ body surface area [BSA] \times min $^{-1}$, then 100 mU \times m $^{-2}$ BSA \times min $^{-1}$) of human insulin (Novolin R, Novo Nordisk), followed by constant infusion of insulin at a rate of 50 mU \times m $^{-2}$ BSA \times min $^{-1}$. Euglycemia (at a blood glucose concentration of ~100 mg/dL) was maintained by variable rate infusion of 20% dextrose (Baxter) enriched to 2.5% with [6,6- 2H] $_2$ glucose. Blood samples to determine plasma metabolite and hormone concentrations as well as glucose and palmitate kinetics were obtained immediately before starting the tracer infusions and every 6–7 min during the last 20 min of the basal period and the HECF; additional blood samples were obtained every 10 min during the HECF to monitor blood glucose concentration. Muscle tissue from the quadriceps femoris was obtained by using a Tilley-Henkel forceps 60 min after starting the glucose tracer infusion (basal period) and 180 min after starting the insulin infusion. The basal and HECF biopsies were taken through separate incisions (~5 cm apart) from the right leg before and after the intervention.

Blood and Tissue Sample Processing and Analyses

Plasma glucose concentration was determined by using an automated glucose analyzer (Yellow Spring Instruments). ELISAs were used to determine insulin (EMD Millipore), C-reactive protein, IL6, and FGF21 (all from R&D Systems) concentrations. Plasma amino acid concentrations were determined by using the EZfaast physiological (free) amino acid kit (Phenomenex) and gas chromatography/mass spectrometry (GC-MS; Hewlett-Packard MSD 5973 system with capillary column) analysis per manufacturer instructions. Total plasma FFA concentration was quantified by using an enzymatic colorimetric assay (Wako Diagnostics). Plasma glucose and palmitate tracer-to-tracee ratios (TTRs) were determined by using GC-MS as previously described (Smith et al., 2015; Mittendorfer et al., 2003b). C3- and C5-acylcarnitine concentrations in plasma were quantified by using liquid chromatography-tandem mass spectrometry (LC-MS/MS; Applied Biosystems Sciex 4000QTRAP with Eclipse C18 column) after adding known amounts of propionyl-L-carnitine (*N-trimethyl-d₃*) and isovaleryl-L-carnitine (*N,N-trimethyl-d₃*) (both purchased from Cambridge Isotope Laboratories) as internal standards and their conversion to methylesters as described (with minor modifications) by Forni et al. (2010).

Western blot analysis was used to quantify the contents of p-AKT^{Ser473}, p-mTOR^{Ser2448}, p-4E-BP1^{Thr37/46}, and p-AMPK^{Thr172} in muscle. Frozen muscle tissue was homogenized in ice-cold cell lysis buffer (Cell Signaling Technology), and proteins were extracted as previously described (Yoshino et al., 2012). Thirty micrograms of protein from each sample were loaded onto polyacrylamide gels (Bio-Rad Laboratories), separated by SDS-PAGE, and transferred to Immobilon-Blot polyvinylidene difluoride membranes (Bio-Rad). The blotted membranes were incubated with the following primary antibodies (all from Cell Signaling Technology, except for TUBULIN, which was purchased from Sigma-Aldrich): rabbit monoclonal anti-phospho-AKT (Ser473) and anti-total-AKT; rabbit polyclonal anti-phospho-mTOR (Ser2448) and anti-total-mTOR; rabbit polyclonal anti-phospho-4E-BP1 (Thr37/46) and anti-total-4E-BP1; rabbit monoclonal anti-phospho-AMPK α (Thr172); rabbit polyclonal anti-total-AMPK α ; and mouse monoclonal anti- α -TUBULIN. All (except for TUBULIN) blots were incubated with a horseradish-peroxidase-conjugated secondary antibody from Cell Signaling Technology; the α -TUBULIN blot was incubated with a horseradish-peroxidase-conjugated secondary antibody from Santa Cruz Biotechnology. Blots were developed by using the Amersham ECL Select Western Blotting Detection Reagent (GE Healthcare Life Sciences). The contents of p-AKT^{Ser473}, p-mTOR^{Ser2448}, p-4E-BP1^{Thr37/46}, and p-AMPK^{Thr172} were expressed relative to a single sample loading control and relative to total AKT, mTOR, 4E-BP1, AMPK, or TUBULIN (p-AKT^{Ser473} only). The results were the same, regardless of the control protein used.

The expression of genes involved in inflammatory (*CD68*, *IL6*, *MCP1*, and *TNF*), oxidative stress defense (*CAT*, *GSTA4*, *SOD1*, and *PRDX3*), lipogenic (*CHREBP*, *ELOVL6*, *FADS1*, *FASN*, *SCD*, and *SREBF1*), and fatty acid oxidation and mitochondrial function (*ACADM*, *COX4/1*, *CPT1B*, *PDK4*, *PPARGC1A*, and *UCP2*) pathways in muscle were analyzed by using the real-time PCR technique after total RNA was isolated from frozen muscle samples by using TRIzol reagent (Invitrogen), quantified spectrophotometrically (NanoDrop 1000, Thermo Scientific), and reverse transcribed (High-Capacity cDNA Reverse Transcription Kit, Invitrogen). Gene expression was determined by using an ABI 7500 RT-PCR system (Invitrogen) and SYBR Green Master Mix (Invitrogen) as previously described (Smith et al., 2014; Yoshino et al., 2014). The expression of each gene was determined by normalizing the cycle threshold value of each sample to the housekeeping control gene, ribosomal protein *RPLP0*. Primer details are listed in Table S3.

Microarray analyses were performed with the GeneChip Human Gene 1.0 ST Array (Affymetrix), and pathways that were significantly altered by the dietary interventions were identified by using the R statistical software package and parametric analysis of gene set enrichment (PAGE), as previously described (Fabbrini et al., 2015; Yoshino et al., 2011; Kim and Volsky, 2005). Gene sets used in PAGE were obtained from http://www.broadinstitute.org/gsea/msigdb/msigdb_index.html (C5: GO [Gene Ontology] gene sets collection). Z scores and p values were calculated for each gene set. Microarray results were deposited in the NCBI GEO database (accession number GEO: GSE73525).

Glucose and Palmitate Kinetics Calculations

The Ra of unlabeled glucose in plasma, which represents the endogenous glucose production rate during basal conditions, was calculated by dividing the glucose tracer infusion rate by the average plasma glucose TTR during the last 20 min of the basal period and the last 20 min of the HECP. During the HECP, total glucose Ra, which equals glucose Rd from plasma, was calculated as the sum of endogenous glucose production plus the rate of infused glucose (dextrose plus tracer). Palmitate Ra in plasma was calculated by dividing the tracer infusion rate by the average plasma palmitate TTR during the last 20 min of the basal period.

Diet Intervention

Subjects attended weekly sessions led by an experienced weight management dietician to ensure compliance with the diet prescription, monitor body weight, and counsel subjects throughout the dietary intervention. The energy content of the initial packed meals given to the weight loss groups was targeted to provide 30% fewer calories than each person's estimated total daily energy expenditure, based on their resting metabolic rate (RMR) multiplied by an activity factor of 1.4 (Black et al., 1996); subsequent meals and dietary intake were adjusted weekly as needed to achieve a 0.5%–1% weight loss per week until 8%–10% was achieved. Once the targeted weight loss goal was achieved, dietary energy intake was modified to maintain a stable body weight for 3–4 weeks before the testing procedures performed at baseline were repeated. Protein intake and macronutrient distribution of the diet were kept constant in accordance with the initial diet prescription throughout the intervention period. In the WM group, each subject's energy intake was adjusted as needed to maintain body weight within 2% of the initial body weight. Target protein intake for the WL group was 0.8 g protein/kg body weight per day and 1.2 g protein/kg body weight per day for subjects in the WL-HP group.

All subjects were provided with a base diet of frozen entrees (eLiving meals, Morrison Healthcare; Lean Cuisine, Nestlé USA; Revel Kitchen) for lunch and dinner. For breakfast, subjects consumed two energy bars (NuGo Nutrition) per day. Subjects in the WL-HP diet group also consumed two servings of a whey protein isolate (Unjury, ProSynthesis Laboratories) per day, whereas subjects in the WL group consumed snacks that provided mostly carbohydrates and fat (in proportion to their contribution to total non-protein dietary energy content of the base diet; i.e., ~63 and 37%, respectively) instead. Additional calories needed to meet each subject's total energy and macronutrient requirements were consumed as fruits, vegetables, dairy products, and starches. Dietary compliance was monitored by having subjects record their dietary intake every day by using the <https://www.myfitnesspal.com> computer app; the study dietician reviewed diet records weekly. In addition, 24-hr urinary urea nitrogen excretion was evaluated before and during the final week of the dietary intervention.

Statistical Analyses

All datasets were tested for normality by using the Kolmogorov-Smirnov test. One-way ANOVA was used to compare basic characteristics of the study subjects, their macronutrient intake, and baseline metabolic characteristics in each of the three groups. Analysis of covariance with the baseline value as covariate was used to evaluate the effect of the dietary interventions on study outcomes that were measured during basal or HECP conditions only. An ANOVA with group (WL versus WL-HP), condition (basal versus clamp), and time (pre- versus post-intervention) as factors, as appropriate, was used to evaluate the effects of dietary interventions on outcomes that were measured during basal conditions and during the HECP; and significant interactions were followed by Tukey's post hoc procedure to locate significant mean differences. A p value ≤ 0.05 was considered statistically significant for all data, except our microarray data. Treatment-induced changes in gene set pathway expression identified by microarray analysis were considered significant if $p \leq 0.001$, and a difference in Z scores > 1.96 was considered a significant difference between the WL and WL-HP groups. Data are presented as mean \pm SEM, unless indicated otherwise.

ACCESSION NUMBERS

The accession number for the microarray data reported in this paper is NCBI GEO: GSE73525.

SUPPLEMENTAL INFORMATION

Supplemental Information includes four figures and three tables and can be found with this article online at <http://dx.doi.org/10.1016/j.celrep.2016.09.047>.

AUTHOR CONTRIBUTIONS

Conceptualization: B.M. and S.K.; Methodology: B.M. and S.K.; Validation: B.M. and J.Y.; Formal Analysis: B.M. and G.I.S.; Investigation: A.O., B.M., B.W.P., D.N.R., G.I.S., J.Y., S.C.K., and S.K.; Writing – Original Draft: B.M. and G.I.S.; Writing – Review and Editing: B.M., G.I.S., J.Y., and S.K.; Visualization: B.M. and G.I.S.; Supervision: B.M. and S.K.; Project Administration: B.M.; Funding Acquisition: B.M. and S.K.

ACKNOWLEDGMENTS

S.K. is a shareholder of Aspire Bariatrics and has served on scientific advisory boards for Takeda Pharmaceuticals and Novo Nordisk.

The authors thank Emily Lake, Janet Winkelmann, Lynda Bowers, and Kathryn Gratza for help with subject recruitment, scheduling, and testing; Kelly Stromsdorfer, Freida Custodio, and Jennifer Shew for their technical assistance; the staff of the Clinical Research Unit for their help in performing the studies; and the study subjects for their participation.

This publication was made possible by NIH grants DK94483, DK56341 (Nutrition and Obesity Research Center), DK20579 (Diabetes Research Center), GM103422 (Biomedical Mass Spectrometry Resource), and UL1TR000448 (Clinical Translational Science Award), including KL2 sub-award TR000450, a Central Society for Clinical and Translational Research Early Career Development Award, and a grant from the Longer Life Foundation.

Received: December 22, 2015

Revised: August 16, 2016

Accepted: September 15, 2016

Published: October 11, 2016

REFERENCES

- Anderson, E.J., Lustig, M.E., Boyle, K.E., Woodlief, T.L., Kane, D.A., Lin, C.T., Price, J.W., 3rd, Kang, L., Rabinovitch, P.S., Szeto, H.H., et al. (2009). Mitochondrial H₂O₂ emission and cellular redox state link excess fat intake to insulin resistance in both rodents and humans. *J. Clin. Invest.* **119**, 573–581.
- Ang, M., Müller, A.S., Wagenlehner, F., Pilatz, A., and Linn, T. (2012). Combining protein and carbohydrate increases postprandial insulin levels but does not improve glucose response in patients with type 2 diabetes. *Metabolism* **61**, 1696–1702.
- Asrih, M., Pellicieux, C., Papageorgiou, I., Lerch, R., and Montessuit, C. (2011). Role of ERK1/2 activation in microtubule stabilization and glucose transport in cardiomyocytes. *Am. J. Physiol. Endocrinol. Metab.* **301**, E836–E843.
- Black, A.E., Coward, W.A., Cole, T.J., and Prentice, A.M. (1996). Human energy expenditure in affluent societies: an analysis of 574 doubly-labelled water measurements. *Eur. J. Clin. Nutr.* **50**, 72–92.
- Boden, G., and Chen, X. (1995). Effects of fat on glucose uptake and utilization in patients with non-insulin-dependent diabetes. *J. Clin. Invest.* **96**, 1261–1268.
- Bose, A., Guilherme, A., Robida, S.I., Nicoloso, S.M., Zhou, Q.L., Jiang, Z.Y., Pomerleau, D.P., and Czech, M.P. (2002). Glucose transporter recycling in response to insulin is facilitated by myosin Myo1c. *Nature* **420**, 821–824.
- Broznick, J.T., Jr., Berkemeier, B.A., and Elmendorf, J.S. (2007). “Actin”g on GLUT4: membrane & cytoskeletal components of insulin action. *Curr. Diabetes Rev.* **3**, 111–122.
- Camporez, J.P., Jornayvaz, F.R., Petersen, M.C., Pesta, D., Guigni, B.A., Serr, J., Zhang, D., Kahn, M., Samuel, V.T., Jurczak, M.J., and Shulman, G.I. (2013). Cellular mechanisms by which FGF21 improves insulin sensitivity in male mice. *Endocrinology* **154**, 3099–3109.
- Chen, X.W., Leto, D., Chiang, S.H., Wang, Q., and Saltiel, A.R. (2007). Activation of RalA is required for insulin-stimulated Glut4 trafficking to the plasma membrane via the exocyst and the motor protein Myo1c. *Dev. Cell* **13**, 391–404.
- Conte, C., Fabbrini, E., Kars, M., Mittendorfer, B., Patterson, B.W., and Klein, S. (2012). Multiorgan insulin sensitivity in lean and obese subjects. *Diabetes Care* **35**, 1316–1321.
- Fabbrini, E., Yoshino, J., Yoshino, M., Magkos, F., Tiemann Luecking, C., Samovski, D., Fraterrigo, G., Okunade, A.L., Patterson, B.W., and Klein, S. (2015). Metabolically normal obese people are protected from adverse effects following weight gain. *J. Clin. Invest.* **125**, 787–795.
- Fazeli, P.K., Lun, M., Kim, S.M., Bredella, M.A., Wright, S., Zhang, Y., Lee, H., Catana, C., Klibanski, A., Patwari, P., and Steihaus, M.L. (2015). FGF21 and the late adaptive response to starvation in humans. *J. Clin. Invest.* **125**, 4601–4611.
- Floyd, J.C., Jr., Fajans, S.S., Conn, J.W., Knopf, R.F., and Rull, J. (1966). Insulin secretion in response to protein ingestion. *J. Clin. Invest.* **45**, 1479–1486.
- Forni, S., Fu, X., Palmer, S.E., and Sweetman, L. (2010). Rapid determination of C4-acylcarnitine and C5-acylcarnitine isomers in plasma and dried blood spots by UPLC-MS/MS as a second tier test following flow-injection MS/MS acylcarnitine profile analysis. *Mol. Genet. Metab.* **101**, 25–32.
- Frimel, T.N., Deivanayagam, S., Bashir, A., O’Connor, R., and Klein, S. (2007). Assessment of intrahepatic triglyceride content using magnetic resonance spectroscopy. *J. Cardiometab. Syndr.* **2**, 136–138.
- Frohnert, B.I., Long, E.K., Hahn, W.S., and Bernlohr, D.A. (2014). Glutathionylated lipid aldehydes are products of adipocyte oxidative stress and activators of macrophage inflammation. *Diabetes* **63**, 89–100.
- Gälman, C., Lundåsen, T., Kharitonov, A., Bina, H.A., Eriksson, M., Hafström, I., Dahlin, M., Amark, P., Angelin, B., and Rudling, M. (2008). The circulating metabolic regulator FGF21 is induced by prolonged fasting and PPAR α activation in man. *Cell Metab.* **8**, 169–174.
- Groop, L.C. (1999). Insulin resistance: the fundamental trigger of type 2 diabetes. *Diabetes Obes. Metab.* **1** (Suppl 1), S1–S7.
- Hattersley, J.G., Pfeiffer, A.F., Roden, M., Petzke, K.J., Hoffmann, D., Rudovich, N.N., Randevara, H.S., Vatish, M., Osterhoff, M., Goegebakan, Ö., et al. (2014). Modulation of amino acid metabolic signatures by supplemented isoenergetic diets differing in protein and cereal fiber content. *J. Clin. Endocrinol. Metab.* **99**, E2599–E2609.
- Houston, D.K., Nicklas, B.J., and Zizza, C.A. (2009). Weighty concerns: the growing prevalence of obesity among older adults. *J. Am. Diet. Assoc.* **109**, 1886–1895.
- Institute of Medicine (2005). *Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids* (Washington, DC: The National Academies Press).
- Iwanaka, N., Egawa, T., Satoubu, N., Karaike, K., Ma, X., Masuda, S., and Hayashi, T. (2010). Leucine modulates contraction- and insulin-stimulated glucose transport and upstream signaling events in rat skeletal muscle. *J. Appl. Physiol.* **108**, 274–282.
- Kim, S.Y., and Volsky, D.J. (2005). PAGE: parametric analysis of gene set enrichment. *BMC Bioinformatics* **6**, 144.
- Kim, K., Yu, M., Han, S., Oh, I., Choi, Y.J., Kim, S., Yoon, K., Jung, M., and Choe, W. (2009). Expression of human peroxiredoxin isoforms in response to cervical carcinogenesis. *Oncol. Rep.* **27**, 1391–1396.
- Kirk, E.P., and Klein, S. (2009). Pathogenesis and pathophysiology of the cardiometabolic syndrome. *J. Clin. Hypertens. (Greenwich)* **11**, 761–765.
- Klein, S. (2001). Outcome success in obesity. *Obes. Res.* **9** (Suppl 4), 354S–358S.
- Klip, A., Sun, Y., Chiu, T.T., and Foley, K.P. (2014). Signal transduction meets vesicle traffic: the software and hardware of GLUT4 translocation. *Am. J. Physiol. Cell Physiol.* **306**, C879–C886.

- Krebs, M., Krssak, M., Bernroider, E., Anderwald, C., Brehm, A., Meyerspeer, M., Nowotny, P., Roth, E., Waldhäusl, W., and Roden, M. (2002). Mechanism of amino acid-induced skeletal muscle insulin resistance in humans. *Diabetes* 51, 599–605.
- Krebs, M., Brunmair, B., Brehm, A., Artwohl, M., Szendroedi, J., Nowotny, P., Roth, E., Fürsinn, C., Promintzer, M., Anderwald, C., et al. (2007). The mammalian target of rapamycin pathway regulates nutrient-sensitive glucose uptake in man. *Diabetes* 56, 1600–1607.
- Laeger, T., Henagan, T.M., Albarado, D.C., Redman, L.M., Bray, G.A., Noland, R.C., Münzberg, H., Hutson, S.M., Gettys, T.W., Schwartz, M.W., and Morrison, C.D. (2014). FGF21 is an endocrine signal of protein restriction. *J. Clin. Invest.* 124, 3913–3922.
- Leidy, H.J., Clifton, P.M., Astrup, A., Wycherley, T.P., Westerterp-Plantenga, M.S., Luscombe-Marsh, N.D., Woods, S.C., and Mattes, R.D. (2015). The role of protein in weight loss and maintenance. *Am. J. Clin. Nutr.* 101, 1320S–1329S.
- Linn, T., Geyer, R., Prassek, S., and Laube, H. (1996). Effect of dietary protein intake on insulin secretion and glucose metabolism in insulin-dependent diabetes mellitus. *J. Clin. Endocrinol. Metab.* 81, 3938–3943.
- Liu, L.Z., Cheung, S.C., Lan, L.L., Ho, S.K., Chan, J.C., and Tong, P.C. (2013). Microtubule network is required for insulin-induced signal transduction and actin remodeling. *Mol. Cell. Endocrinol.* 365, 64–74.
- Magkos, F., Patterson, B.W., Mohammed, B.S., Klein, S., and Mittendorfer, B. (2007). Women produce fewer but triglyceride-rich very low-density lipoproteins than men. *J. Clin. Endocrinol. Metab.* 92, 1311–1318.
- Manders, R.J., Hansen, D., Zorenc, A.H., Dendale, P., Kloek, J., Saris, W.H., and van Loon, L.J. (2014). Protein co-ingestion strongly increases postprandial insulin secretion in type 2 diabetes patients. *J. Med. Food* 17, 758–763.
- Markan, K.R., Naber, M.C., Ameka, M.K., Anderegg, M.D., Mangelsdorf, D.J., Kiewer, S.A., Mohammadi, M., and Potthoff, M.J. (2014). Circulating FGF21 is liver derived and enhances glucose uptake during refeeding and overfeeding. *Diabetes* 63, 4057–4063.
- Mashili, F.L., Austin, R.L., Deshmukh, A.S., Fritz, T., Caidahl, K., Bergdahl, K., Zierath, J.R., Chibalin, A.V., Moller, D.E., Kharitonkov, A., and Krook, A. (2011). Direct effects of FGF21 on glucose uptake in human skeletal muscle: implications for type 2 diabetes and obesity. *Diabetes Metab. Res. Rev.* 27, 286–297.
- Mittendorfer, B., Liem, O., Patterson, B.W., Miles, J.M., and Klein, S. (2003a). What does the measurement of whole-body fatty acid rate of appearance in plasma by using a fatty acid tracer really mean? *Diabetes* 52, 1641–1648.
- Mittendorfer, B., Patterson, B.W., and Klein, S. (2003b). Effect of sex and obesity on basal VLDL-triacylglycerol kinetics. *Am. J. Clin. Nutr.* 77, 573–579.
- Muio, D.M., and Neuffer, P.D. (2012). Lipid-induced mitochondrial stress and insulin action in muscle. *Cell Metab.* 15, 595–605.
- Newgard, C.B., An, J., Bain, J.R., Muehlbauer, M.J., Stevens, R.D., Lien, L.F., Haqq, A.M., Shah, S.H., Arlotto, M., Slentz, C.A., et al. (2009). A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. *Cell Metab.* 9, 311–326.
- Pedersen, B.K. (2007). IL-6 signalling in exercise and disease. *Biochem. Soc. Trans.* 35, 1295–1297.
- Petersen, K.F., and Shulman, G.I. (2002). Pathogenesis of skeletal muscle insulin resistance in type 2 diabetes mellitus. *Am. J. Cardiol.* 90 (5A), 11G–18G.
- Phillips, S.K., Rook, K.M., Siddle, N.C., Bruce, S.A., and Woledge, R.C. (1993). Muscle weakness in women occurs at an earlier age than in men, but strength is preserved by hormone replacement therapy. *Clin. Sci.* 84, 95–98.
- Raza, H., Robin, M.A., Fang, J.K., and Avadhani, N.G. (2002). Multiple isoforms of mitochondrial glutathione S-transferases and their differential induction under oxidative stress. *Biochem. J.* 366, 45–55.
- Rietman, A., Schwarz, J., Tomé, D., Kok, F.J., and Mensink, M. (2014). High dietary protein intake, reducing or eliciting insulin resistance? *Eur. J. Clin. Nutr.* 68, 973–979.
- Robinson, M.M., Soop, M., Sohn, T.S., Morse, D.M., Schimke, J.M., Klaus, K.A., and Nair, K.S. (2014). High insulin combined with essential amino acids stimulates skeletal muscle mitochondrial protein synthesis while decreasing insulin sensitivity in healthy humans. *J. Clin. Endocrinol. Metab.* 99, E2574–E2583.
- Roden, M., Price, T.B., Perseghin, G., Petersen, K.F., Rothman, D.L., Cline, G.W., and Shulman, G.I. (1996). Mechanism of free fatty acid-induced insulin resistance in humans. *J. Clin. Invest.* 97, 2859–2865.
- Saha, A.K., Xu, X.J., Balon, T.W., Brandon, A., Kraegen, E.W., and Ruderman, N.B. (2011). Insulin resistance due to nutrient excess: is it a consequence of AMPK downregulation? *Cell Cycle* 10, 3447–3451.
- Samson, M.M., Meeuwse, I.B., Crowe, A., Dessens, J.A., Duursma, S.A., and Verhaar, H.J. (2000). Relationships between physical performance measures, age, height and body weight in healthy adults. *Age Ageing* 29, 235–242.
- Schooneman, M.G., Vaz, F.M., Houten, S.M., and Soeters, M.R. (2013). Acylcarnitines: reflecting or inflicting insulin resistance? *Diabetes* 62, 1–8.
- Schröder, E., Brennan, J.P., and Eaton, P. (2008). Cardiac peroxiredoxins undergo complex modifications during cardiac oxidant stress. *Am. J. Physiol. Heart Circ. Physiol.* 295, H425–H433.
- Schwingshackl, L., and Hoffmann, G. (2013). Long-term effects of low-fat diets either low or high in protein on cardiovascular and metabolic risk factors: a systematic review and meta-analysis. *Nutr. J.* 12, 48.
- Sluijs, I., Beulens, J.W., van der A, D.L., Spijkerman, A.M., Grobbee, D.E., and van der Schouw, Y.T. (2010). Dietary intake of total, animal, and vegetable protein and risk of type 2 diabetes in the European Prospective Investigation into Cancer and Nutrition (EPIC)-NL Study. *Diabetes Care* 33, 43–48.
- Smith, G.I., Yoshino, J., Reeds, D.N., Bradley, D., Burrows, R.E., Heisey, H.D., Moseley, A.C., and Mittendorfer, B. (2014). Testosterone and progesterone, but not estradiol, stimulate muscle protein synthesis in postmenopausal women. *J. Clin. Endocrinol. Metab.* 99, 256–265.
- Smith, G.I., Yoshino, J., Stromsdorfer, K.L., Klein, S.J., Magkos, F., Reeds, D.N., Klein, S., and Mittendorfer, B. (2015). Protein ingestion induces muscle insulin resistance independent of leucine-mediated mTOR activation. *Diabetes* 64, 1555–1563.
- Tinker, L.F., Sarto, G.E., Howard, B.V., Huang, Y., Neuhaus, M.L., Mossavar-Rahmani, Y., Beasley, J.M., Margolis, K.L., Eaton, C.B., Phillips, L.S., and Prentice, R.L. (2011). Biomarker-calibrated dietary energy and protein intake associations with diabetes risk among postmenopausal women from the Women's Health Initiative. *Am. J. Clin. Nutr.* 94, 1600–1606.
- Tremblay, F., Jacques, H., and Marette, A. (2005). Modulation of insulin action by dietary proteins and amino acids: role of the mammalian target of rapamycin nutrient sensing pathway. *Curr. Opin. Clin. Nutr. Metab. Care* 8, 457–462.
- Tsai, S., Sitzmann, J.M., Dastidar, S.G., Rodriguez, A.A., Vu, S.L., McDonald, C.E., Academia, E.C., O'Leary, M.N., Ashe, T.D., La Spada, A.R., and Kennedy, B.K. (2015). Muscle-specific 4E-BP1 signaling activation improves metabolic parameters during aging and obesity. *J. Clin. Invest.* 125, 2952–2964.
- Whitaker, H.C., Patel, D., Howat, W.J., Warren, A.Y., Kay, J.D., Sangan, T., Marioni, J.C., Mitchell, J., Aldridge, S., Luxton, H.J., et al. (2013). Peroxiredoxin-3 is overexpressed in prostate cancer and promotes cancer cell survival by protecting cells from oxidative stress. *Br. J. Cancer* 109, 983–993.
- Wolfe, R.R., Miller, S.L., and Miller, K.B. (2008). Optimal protein intake in the elderly. *Clin. Nutr.* 27, 675–684.
- Wycherley, T.P., Moran, L.J., Clifton, P.M., Noakes, M., and Brinkworth, G.D. (2012). Effects of energy-restricted high-protein, low-fat compared with standard-protein, low-fat diets: a meta-analysis of randomized controlled trials. *Am. J. Clin. Nutr.* 96, 1281–1298.
- Xu, J., Lloyd, D.J., Hale, C., Stanislaus, S., Chen, M., Sivits, G., Vonderfecht, S., Hecht, R., Li, Y.S., Lindberg, R.A., et al. (2009). Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. *Diabetes* 58, 250–259.
- Yoshino, J., Mills, K.F., Yoon, M.J., and Imai, S. (2011). Nicotinamide mononucleotide, a key NAD(+) intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice. *Cell Metab.* 14, 528–536.

Yoshino, J., Conte, C., Fontana, L., Mittendorfer, B., Imai, S., Schechtman, K.B., Gu, C., Kunz, I., Rossi Fanelli, F., Patterson, B.W., and Klein, S. (2012). Resveratrol supplementation does not improve metabolic function in nonobese women with normal glucose tolerance. *Cell Metab.* *16*, 658–664.

Yoshino, J., Almeda-Valdes, P., Patterson, B.W., Okunade, A.L., Imai, S., Mittendorfer, B., and Klein, S. (2014). Diurnal variation in insulin sensitivity of

glucose metabolism is associated with diurnal variations in whole-body and cellular fatty acid metabolism in metabolically normal women. *J. Clin. Endocrinol. Metab.* *99*, E1666–E1670.

Zaid, H., Antonescu, C.N., Randhawa, V.K., and Klip, A. (2008). Insulin action on glucose transporters through molecular switches, tracks and tethers. *Biochem. J.* *413*, 201–215.